Braquiterapia
Gold-DOT
Fiducial01 / 01
Gold powder-polymer (PMMA) composite — gold content ~1/20 of conventional pure-gold markers (prototype-confirmed)
CT visibility: 7,013 HU measured in prototype → development target ≥7,200 HU
Proton beam dose reduction: 8.5% measured in prototype → development target ≤7%
Carbon-ion beam dose reduction: 7.2% measured in prototype → approaching target ≤7%
CT distortion pixel ratio: 23% measured in prototype → development target ≤15%
Anti-migration structure — stable positional reproducibility throughout fractionated treatment
Joint MOU research ongoing with Gunma University Hospital, Japan
Coming Soon
Gold powder-polymer composite marker for prostate cancer particle therapy — prototype testing confirmed 7,013 HU CT visibility, 8.5% proton and 7.2% carbon-ion dose reduction vs. up to 44.3% for pure-gold markers, with development targets of ≥7,200 HU and ≤7%.
Gold-DOT is a next-generation tumor localization marker designed to overcome the limitations of conventional pure-gold markers in particle radiation therapy for prostate cancer. Manufactured as a gold powder-polymer (PMMA) composite, it achieves a gold content of approximately 1/20 that of conventional pure-gold markers — confirmed in preliminary prototype testing. The technical foundation is a peer-reviewed 2009 paper by the RaphaRAD founding team (Lim et al., Int. J. Radiation Oncology Biol. Phys., Vol. 74, No. 5) demonstrating that conventional pure-gold markers attenuate proton beams by up to 44.3%, while a gold powder-based approach can suppress dose interference to approximately 5% or below.
Preliminary prototype testing confirmed: CT visibility of 7,013 HU, proton beam dose reduction rate of 8.5%, and carbon-ion beam dose reduction rate of 7.2% — already approaching commercially competitive levels. Current development targets are CT visibility ≥7,200 HU, proton/carbon-ion dose reduction ≤7%, and CT distortion pixel ratio ≤15%, to be validated at the National Cancer Center and KOLAS-accredited institutions.
Joint R&D is underway with Gunma University Hospital (Japan) via MOU, and the minimal gold content delivers significant cost competitiveness for particle therapy centers.
- Particle therapy tumor tracking: prototype confirmed 7,013 HU CT visibility (target ≥7,200 HU) and proton dose reduction 8.5% / carbon-ion 7.2% (target ≤7%)
- CT distortion pixel ratio 23% in prototype — development target ≤15% for more accurate treatment planning
- Gold content ~1/20 of conventional pure-gold markers (prototype-confirmed) — significant cost advantage for particle therapy centers
- Anti-migration fixation structure ensures stable position reproducibility across all fractions
Productos relacionados
La navegacion conecta de forma natural con los productos vecinos dentro del mismo portafolio
La pagina de detalle no termina en un callejon sin salida; sigue hacia tratamiento, QA y proteccion.
Protones
Pro-MI
QA braqui
BIM
